Atlas Trials

Relapsed Diffuse Large B Cell Lymphoma

19 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Relapsed Diffuse Large B Cell Lymphoma

RecordFirmDate
Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab (NCT05267054)BeiGene2022-04-25
Trial of Loncastuximab Tesirine in High Risk Diffuse Large B-cell Lymphoma Post Transplant (NCT05222438)Barbara Ann Karmanos Cancer Institute2022-04-08
Copanlisib Plus Venetoclax in R/R DLBCL (NCT04572763)Dana-Farber Cancer Institute2021-09-08
Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib (NCT05068440)BeiGene2021-08-11
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (NCT04920617)ImmunoVaccine Technologies, Inc. (IMV Inc.)2021-06-18
DALY II USA/ MB-CART2019.1 for DLBCL (NCT04792489)Miltenyi Biomedicine GmbH2021-05-25
Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL) (NCT04833114)GWT-TUD GmbH2021-04-30
Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCL (NCT04659434)Qian Wenbin2020-12-10
Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (NCT04384484)ADC Therapeutics S.A.2020-09-16
A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma (NCT03688152)Incyte Corporation2018-12-03
PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma (NCT03488251)Molecular Templates, Inc.2018-08-20
Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL (NCT03305445)Icahn School of Medicine at Mount Sinai2018-05-14
Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose Therapy (NCT03422523)University Hospital Southampton NHS Foundation Trust2018-05-09
A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (NCT03136497)Hackensack Meridian Health2017-09-05
Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05) (NCT02658968)Nordic Nanovector2017-03-02
Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma (NCT02348216)Kite, A Gilead Company2015-04-21
Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (NCT02077166)Pharmacyclics LLC.2014-03-13

Track Relapsed Diffuse Large B Cell Lymphoma automatically

Every clearance here is in the API, with alerts when new ones post.